The antibody aducanumab reduces Abeta plaques in Alzheimer's disease.
Article Details
- CitationCopy to clipboard
Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A
The antibody aducanumab reduces Abeta plaques in Alzheimer's disease.
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.
- PubMed ID
- 27582220 [ View in PubMed]
- Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-beta (Abeta) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Abeta to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Abeta. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Abeta, and reduce soluble and insoluble Abeta in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Abeta in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Aducanumab Amyloid beta A4 protein Protein Humans UnknownAntagonistBinderAntibodyDetails